We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04590872
Previous Study | Return to List | Next Study

An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04590872
Recruitment Status : Recruiting
First Posted : October 19, 2020
Last Update Posted : July 27, 2022
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:
This phase I trial investigates the side effects of PIpepTolDC vaccine in treating patients with type 1 diabetes who use insulin and don't have any other diabetes-related health complications. Type 1 diabetes is an autoimmune disease. This means that the immune system, which usually protects against foreign invaders like bacteria and viruses, attacks the body's insulin-producing betacells in the pancreas (autoimmune response). Overtime, the beta cells are destroyed by the immune system. To stay alive, people with type 1 diabetes must use insulin. PIpepTolDC vaccine is a type of immunotherapy (a treatment that uses a person's own immune system) that works like an allergy shot. The vaccine is made using one's own immune cells (dendritic cells) and a beta cell protein. The vaccine may teach the immune system to stop attacking the beta cells, which may help the beta cells recover and make enough insulin to control blood sugar levels. The vaccine may also help reduce future type 1 diabetes related complications.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Biological: Tolerogenic Dendritic Cell Vaccine Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Evaluate the Safety and Feasibility of Autologous Tolerogenic Dendritic Cells Loaded With Proinsulin Peptide (C19-A3) in Patients With Type 1 Diabetes
Actual Study Start Date : June 16, 2022
Estimated Primary Completion Date : October 10, 2023
Estimated Study Completion Date : October 10, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Autologous Tolerogenic Dendritic Cell with Proinsulin Peptide (PIpepTolDC)
After completion of leukapheresis, patients receive a prime dose of PIpepTolDC intradermally (ID) on Day 0, followed by a boost dose of PIpepTolDC ID on Day 28.
Biological: Tolerogenic Dendritic Cell Vaccine

Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: Up to 2 years ]
    Toxicity and adverse events (except hypoglycemia and diabetic ketoacidosis [DKA]) will be recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Hypoglycemia events and DKA will be defined per American Diabetes Association (ADA) grading systems.Observed toxicities will be summarized by type, severity (by CTCAE v 5.0 and nadir or maximum values for lab measures), date of onset, duration, reversibility, and attribution.

  2. Apheresis duration [ Time Frame: up to 2 years ]
    Measured in hours.

  3. Number of CD14+ monocytes [ Time Frame: up to 2 years ]
    Number of CD14+ monocytes collected during apheresis

  4. TolDC recovery after culture [ Time Frame: up to 2 years ]
    Number of TolDC generated from CD14+ monocytes

  5. Number of successful manufactured products [ Time Frame: Up to 2 years ]
    Number of manufactured products that meet the required cell dose/day, sterility (e.g. endotoxin and gram staining), and viability compared to the total number of products manufactured.

Secondary Outcome Measures :
  1. Change in stimulated C-peptide area under the curve [ Time Frame: Baseline up to 2 years of follow up ]
    Assessed via 2-hr mixed meal tolerance test (MMTT). C-peptide preservation is defined as the maintenance of baseline C-peptide levels.

  2. Change in interferon (IFN)-gamma and IL-10 producing CD4+ T cells [ Time Frame: Baseline up to 2 years of follow up ]
    Will be assessed in response to pro-insulin peptide C19-A3, and assessed via cytokine enzyme-linked immunosorbent spot assay.

  3. Change in T cell responsiveness [ Time Frame: Baseline up to 2 years of follow up ]
    Will assess for changes in T cell responsiveness to pro-insulin peptide C19-A3 compared to other antigens. Assessed via Lymphocyte Simulation Test.

  4. Change in the number of CD8+ autoreactive T cells [ Time Frame: Baseline up to 2 years of follow up ]
    Assessed via quantum dot (Q-DOT) nanotechnology assay.

  5. Change in immune phenotype [ Time Frame: Baseline up to 2 years of follow up ]
    Will analyze for changes in immune cell populations via flow cytometry

  6. Change in islet autoantibodies [ Time Frame: Baseline up to 2 years of follow up ]
    Will analyze for changes in IAA, GAA, IA-2A, ZnT8A via enzyme-linked immunosorbent assay.

  7. Change in glycosylated hemoglobin A1c (HbA1c) levels [ Time Frame: Baseline up to 2 years of follow up ]
    HbA1c levels will be assessed via blood test

  8. Change in exogenous insulin use (units/kg) [ Time Frame: Baseline up to 2 years of follow up ]
    Insulin usage will be recorded daily from the insulin pump and/or participant insulin use logs. The mean daily insulin usage over the 10 consecutive days (IU units/kg body weight/day) preceding the clinic visit will be calculated for each participant.

  9. Change in blood glucose levels [ Time Frame: Baseline up to 2 years of follow up ]
    Will include clinically important/severe hypoglycemia, hyperglycemia and DKA events as assessed by ADA grading systems. Levels of glucose will be assessed from bloods samples taken during the MMTT and from insulin pump/participant insulin logs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willingness to undergo leukapheresis
  • Willingness to be followed for about 2 years post-prime dose
  • For participants who have a personal continuous glucose monitoring device (CGMD): Willingness to wear a second CGMD during mandated study CGMD visits
  • Diagnosis of type 1 diabetes based on American Diabetes Association (ADA) criteria
  • Historical presence of at least one type-1 diabetes associated autoantibody

    • GAD specific autoantibodies (glutamic acid decarboxylase autoantibodies [GADA])
    • Islet cell cytoplasmic autoantibodies (ICA)
    • Islet-antigen 2 specific autoantibody (IA-2A)
    • Zinc transporter 8 specific autoantibody (ZNT8A); and/or
    • Insulin autoantibody (IAA) (must have been obtained within 7 days of initiating exogenous insulin replacement therapy)
  • Time from diagnosis to screening mixed meal tolerance test (MMTT) must be >= 1 year but =< 4 years
  • Stable glycemic control per participant's physician
  • HbA1c =< 7.5% (=< 58 mmol/mol)
  • Non-fasting C-peptide > 0.017 nmol/L
  • Stimulated peak C-peptide levels > 0.2 nmol/L from a 2-hour screening MMTT
  • Positive for *04:01 allele, *04:02 allele and/or *04:04 allele at the human leukocyte antigen (HLA)-DRB1 gene locus
  • Does not possess the protective HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype
  • Adequate self-assessment of blood glucose values and recording of glucose values, and administered insulin doses as deemed sufficient by the participant's physician
  • No diagnosis of type 1 diabetes related microvascular/macrovascular complications (e.g. nephropathy, retinopathy and neuropathy)
  • Deemed acceptable for autologous cell collection (i.e. leukapheresis)
  • Only for those who are naive to CGMD use: Deemed able to correctly use a CGM device following training session with a certified diabetes educator and manufacturer representative
  • Must meet organ function criteria

Exclusion Criteria:

  • Other investigational agents, biologics
  • Anti-inflammatory therapy

    • Exception: Over-the-counter (OTC) anti-inflammatory agents (e.g. ibuprofen, Tylenol) are generally allowed. However, those requiring chronic OTC anti-inflammatory agents and unable to stop during mandated CGMD study visits will be excluded
  • Systemic corticosteroids within 28 days prior to leukapheresis
  • Systemic immunosuppressive therapy (e.g. cyclosporine-A, cyclophosphamide)
  • Monoclonal antibody therapy
  • Allergen immunotherapy within 28 days prior to leukapheresis
  • Vaccine(s) within 28 days prior to leukapheresis
  • Prior allogeneic organ transplant
  • Beta-cell stimulants (e.g. sulfonylureas such as glimepiride), glucagon-like peptide-1 agonists, dipeptidyl peptidase-IV inhibitors (exception: Those with acute exposure to these agents during T1D misdiagnosis may be permitted per PI discretion)
  • Insulin sensitizers (e.g. metformin, thiazolidinediones) within 2 months of leukapheresis
  • History of insulin sensitizer use (e.g. metformin, thiazolidinediones) ≥ 2 months
  • Other autoimmune/inflammatory disorders (exceptions: (i) Type 1 diabetes. (ii) Asymptomatic patients with incidental autoantibody titres may be permitted per PI discretion)
  • Other autoimmune/inflammatory disorders (exception type 1 diabetes)
  • Active infection requiring antibiotics and/or anti-virals
  • Known history of HIV, HBV, HCV, HTLV, syphilis
  • History of positive purified protein derivative (PPD) skin test
  • History of atopy requiring systemic treatment and/or history of severe allergic reactions
  • History or current malignancy
  • Unstable cardiac disease
  • History of vascular disease (e.g. deep vein thrombosis, stroke)
  • Clinically significant uncontrolled illness
  • Females only: pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04590872

Layout table for location contacts
Contact: Study Coordinator 866-444-7538 DL-TolDC@coh.org

Layout table for location information
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Behrouz Salehian-Dardashti    866-444-7538    DL-TolDC@coh.org   
Principal Investigator: Behrouz Salehian-Dardashti         
Sponsors and Collaborators
City of Hope Medical Center
Layout table for investigator information
Principal Investigator: Behrouz alehian-Dardashti, MD City of Hope Medical Center
Layout table for additonal information
Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT04590872    
Other Study ID Numbers: 18279
First Posted: October 19, 2020    Key Record Dates
Last Update Posted: July 27, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases